Liven Pharma Limited (PSX:LIVEN)

Liven Pharma Statistics

Total Valuation

Liven Pharma has a market cap or net worth of PKR 5.30 billion. The enterprise value is 5.33 billion.

Market Cap	5.30B
Enterprise Value	5.33B

Important Dates

The last earnings date was Sunday, November 9, 2025.

Earnings Date	Nov 9, 2025
Ex-Dividend Date	n/a

Share Statistics

Liven Pharma has 93.04 million shares outstanding. The number of shares has increased by 174,375.69% in one year.

Current Share Class	93.04M
Shares Outstanding	93.04M
Shares Change (YoY)	+174,375.69%
Shares Change (QoQ)	-9.67%
Owned by Insiders (%)	7.21%
Owned by Institutions (%)	4.27%
Float	85.98M

Valuation Ratios

PE Ratio	n/a
Forward PE	n/a
PS Ratio	41.66
PB Ratio	8.37
P/TBV Ratio	8.48
P/FCF Ratio	n/a
P/OCF Ratio	n/a
PEG Ratio	n/a

Enterprise Valuation

EV / Earnings	-9.12
EV / Sales	41.87
EV / EBITDA	n/a
EV / EBIT	n/a
EV / FCF	-216.98

Financial Position

The company has a current ratio of 1.64, with a Debt / Equity ratio of 0.05.

Current Ratio	1.64
Quick Ratio	0.19
Debt / Equity	0.05
Debt / EBITDA	n/a
Debt / FCF	-1.41
Interest Coverage	-676.45

Financial Efficiency

Return on equity (ROE) is -84.49% and return on invested capital (ROIC) is -39.02%.

Return on Equity (ROE)	-84.49%
Return on Assets (ROA)	-35.12%
Return on Invested Capital (ROIC)	-39.02%
Return on Capital Employed (ROCE)	-67.13%
Revenue Per Employee	3.10M
Profits Per Employee	-14.26M
Employee Count	41
Asset Turnover	0.15
Inventory Turnover	0.90

Taxes

In the past 12 months, Liven Pharma has paid 92.27 million in taxes.

Income Tax	92.27M
Effective Tax Rate	n/a

Stock Price Statistics

The stock price has decreased by -2.88% in the last 52 weeks. The beta is -0.21, so Liven Pharma's price volatility has been lower than the market average.

Beta (5Y)	-0.21
52-Week Price Change	-2.88%
50-Day Moving Average	62.75
200-Day Moving Average	72.08
Relative Strength Index (RSI)	43.21
Average Volume (20 Days)	260,888

Short Selling Information

Short Interest	n/a
Short Previous Month	n/a
Short % of Shares Out	n/a
Short % of Float	n/a
Short Ratio (days to cover)	n/a

Income Statement

In the last 12 months, Liven Pharma had revenue of PKR 127.27 million and -584.46 million in losses. Loss per share was -8.37.

Revenue	127.27M
Gross Profit	15.82M
Operating Income	-491.71M
Pretax Income	-492.19M
Net Income	-584.46M
EBITDA	-465.93M
EBIT	-491.71M
Loss Per Share	-8.37

Balance Sheet

The company has 7.88 million in cash and 34.67 million in debt, giving a net cash position of -26.78 million or -0.29 per share.

Cash & Cash Equivalents	7.88M
Total Debt	34.67M
Net Cash	-26.78M
Net Cash Per Share	-0.29
Equity (Book Value)	633.86M
Book Value Per Share	6.81
Working Capital	57.53M

Cash Flow

In the last 12 months, operating cash flow was -1.72 million and capital expenditures -22.84 million, giving a free cash flow of -24.56 million.

Operating Cash Flow	-1.72M
Capital Expenditures	-22.84M
Free Cash Flow	-24.56M
FCF Per Share	-0.26

Margins

Gross Margin	12.43%
Operating Margin	-386.34%
Pretax Margin	-386.72%
Profit Margin	n/a
EBITDA Margin	n/a
EBIT Margin	n/a
FCF Margin	n/a

Dividends & Yields

Liven Pharma does not appear to pay any dividends at this time.

Dividend Per Share	n/a
Dividend Yield	n/a
Dividend Growth (YoY)	n/a
Years of Dividend Growth	n/a
Payout Ratio	n/a
Buyback Yield	-174,375.69%
Shareholder Yield	-174,375.69%
Earnings Yield	-11.02%
FCF Yield	-0.46%

Fair Value

There are several formulas that can be used to estimate the intrinsic value of a stock.

Lynch Fair Value	n/a
Lynch Upside	n/a
Graham Number	n/a
Graham Upside	n/a

Stock Splits

This stock does not have any record of stock splits.

Last Split Date	n/a
Split Type	n/a
Split Ratio	n/a

Scores

Liven Pharma has an Altman Z-Score of 5.43 and a Piotroski F-Score of 2.

Altman Z-Score	5.43
Piotroski F-Score	2